The prospect of a pill rather than an injection is obviously appealing to some people, but will fear of needles be enough to ...

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has been struggling during the past year. Its financial results - ...

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...

Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the company and its stock ...

Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.

Trump proposed a change to Medicare price talks that has long been sought after by the pharmaceutical industry.

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Novo Nordisk, the Danish maker of Ozempic and Wegovy, announced Tuesday that it has asked the Food and Drug Administration to ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), ...

Novo Nordisk's booming obesity drugs & diabetes portfolio make it a top growth play. Click here to read an analysis of NVO ...

Beleaguered Belgian biotech Galapagos said yesterday that its CEO, Paul Stoffels, plans to retire upon the appointment of his ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...